Promacta eltrombopag regulatory update

GSK submitted an NDA to FDA for Promacta eltrombopag to treat idiopathic thrombocytopenic purpura (ITP). The milestone triggered a $1 million payment to LGND from GSK, which has worldwide rights to th...